<DOC>
	<DOCNO>NCT02388633</DOCNO>
	<brief_summary>Severe hypercholesterolemia produce condition heterozygous familial hypercholesterolemia associate multiple complication include premature atherosclerotic disease . There evidence microvascular perfusion , particularly flow reserve , critical organ limit due abnormality plasma viscosity , abnormal RBC deformability , imbalance vasodilator vasoconstrictor . There little currently know acute change microvascular blood flow microvascular rheology occur response plasmapharesis use patient lower critically elevate cholesterol level . Our research group pioneer CEU method assess myocardial skeletal muscle perfusion , previously demonstrate pre-clinical model acute hyperlipidemia produce reduction microvascular RBC transit rate . In study , investigator assess acute change microvascular perfusion patient undergo clinically-indicated plasmapharesis .</brief_summary>
	<brief_title>Acute Microvascular Changes With LDL Apheresis</brief_title>
	<detailed_description>Subjects schedule planned apheresis treatment severe hypercholesterolemia recruit study . They undergo screen evaluation , include medical history , physical examination , ECG , limited echocardiogram evaluate exclusion criterion . Before apheresis procedure , blood sample obtain plasma marker inflammation , erythrocyte deformability , plasma viscosity . Contrast enhance ultrasound perfusion image perform evaluate blood flow myocardium rest , well forearm skeletal muscle mild isometric exercise ( 50 % maximal grip , 0.2 Hz ) . Flow mediate vasodilation perform . The subject undergo plan apheresis procedure . Within 2 hour completion apheresis , blood collection CEU repeat . Plasma lipid available part standard apharesis protocol .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>hypercholesterolemia ( LDL &gt; 200 mg/dL ) clinicallyindicated aphersis hyperlipidemia age &gt; 18 y.o . pregnant lactating female hypersensitivity ultrasound contrast agent evidence right leave bidirectional shunt anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>